The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.

CEO Robert Blum is “very clear” that the company, which is on track for U.S. approval in September for aficamten to treat a ...

SAN FRANCISCO — Cytokinetics CEO Robert Blum is very clear. The company — on track to secure U.S. approval in September for a drug to treat a serious heart condition — is not for sale.

with results expected in the first half of this year as may potentially support the use of aficamten as monotherapy," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "In ...

with results expected in the first half of this year as may potentially support the use of aficamten as monotherapy,” said Robert I. Blum, Cytokinetics' President and Chief Executive Officer.“ ...

Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J ...

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.

Cytokinetics should hear back from the FDA ... In the company's third-quarter results update, chief executive Robert Blum said that aficamten has a "next-in-class safety and efficacy profile ...